Examples of using Bleeding risk in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk see section 4.4.
clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B
when the thromboembolic risk is low and the bleeding risk is high see section 4.4.
which increases the bleeding risk and in some cases may lead to bleeding. .
ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk.
you should be treated with a reduced dose of 150 mg Pradaxa taken once a day as 2 capsules of 75 mg, because your bleeding risk may be increased.
you should be treated with a reduced dose of 75 mg Pradaxa because your bleeding risk may be increased.
If you are taking verapamil-containing medicines, you should be treated with a reduced Pradaxa dose of 220 mg taken as one 110 mg capsule twice a day, because your bleeding risk may be increased.
If you are taking verapamil-containing medicines, you should be treated with a reduced Pradaxa dose of 220 mg taken as one 110 mg capsule twice a day, because your bleeding risk may be increased.
concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year.
other medicinal products associated with bleeding risk such as pentoxifylline see section 4.5.
other medicinal products associated with bleeding risk such as pentoxifylline see section 4.5.
measuring bleeding risk with the CRUSADE scale,
Pradaxa should only be given if the benefit outweighs bleeding risks.
due to a higher bleeding risk see information on bleeding in section 4.4 and on the STREAM study in section 5.1.
This particularly includes the following situations with increased bleeding risk.
No evidence of increased bleeding risk has been observed in clinical trials with telavancin.
The expected effect of excessive Possia dosing is prolonged duration of bleeding risk associated with platelet inhibition.
Cangrelor should be used with caution in patients with disease states associated with an increased bleeding risk.
If you have an increased bleeding risk, as could be the case in the following situations.